Researchers are addressing the issue of elevated HAS2 activity in tumor cells through various approaches, including the use of long noncoding RNA HAS2-AS1, CRISPR/Cas9-mediated HAS2 knockout system, proteolysis targeting chimeric (PROTAC) technology [189]. The gene discussed is HAS2; the disease is neoplasm.